DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-30 filed October 03, 2024 are currently pending.
Priority
Acknowledgment is made of the national stage entry of PCT/US2023/063745 filed 03/04/2023 which claims priority to U.S. Provisional Application 63327058 filed 04/04/2022.
Information Disclosure Statement
The information disclosure statement (IDS) submitted on 10/03/2024 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.
Claim Rejections - 35 USC § 112-Paragraph A
Claims 26-30 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for treating the LRRK2 mediated disorder Parkinson’s disease and Alzheimer’s disease in a subject in need comprising administering a compound with the chemical structure of Formula (I) to said subject in need, does not reasonably provide enablement for the prevention of Alzheimer’s disease and Parkinson’s disease in the disclosed subject. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.
Pursuant to In re Wands, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988), one considers the following factors to determine whether undue experimentation is required: (1) The breadth of the claims, (2) The nature of the invention, (3) The state of the prior art, (4) The level of one of ordinary skill, (5) The level of predictability in the art, (6) The amount of direction provided by the inventor, (7) The existence of working examples, (8) The quantity of experimentation needed to make or use the invention based on the content of the disclosure.
Some experimentation is not fatal; the issue is whether the amount of experimentation is “undue”; see In re Vaeck, 20 USPQ2d 1438, 1444.
The analysis is as follows:
(1) The breadth of the claims: The breadth of the claims is directed to the treatment of Parkinson’s disease, Alzheimer’s disease and Amyotrophic Lateral Sclerosis as well as the prevention of developing Parkinson’s disease or Alzheimer’s disease or Amyotrophic Lateral Sclerosis in a subject in need comprising administering a therapeutically effective amount of a compound of Formula (I) to a subject in need.
(2) The nature of the invention: The nature of the invention is treating the LRRK2 mediated disorder Parkinson’s disease, Alzheimer’s disease or Amyotrophic Lateral Sclerosis in a subject in need comprising administering a therapeutically effective amount of a compound of Formula (I).
(3): The State of the Prior Art:
Garofalo (WO2019/222173 published 11/12/2019) represents the state of the prior art of treating disorders mediated by LRRK2 comprising administering a therapeutically effective amount of an LRRK2 inhibitor (abstract, claim 1, 88-89, 91, 94-99). Garofalo teaches that compounds that comprise the structure of PTM-I are efficacious for inhibiting LRRK2 and diseases mediated by LRRK2 in a subject in need, such as Parkinson’s disease and Alzheimer’s disease (abstract, claim 1, 88-89, 91, 94-99). Embraced within Garofalo is Example 38 shown above which comprises the same substituted indazole pharmacophore as the presently claimed Formula (I) (page 112-113; Table 1). Nowhere within the boundaries of the reference does Garofalo disclose that the administration of an indazole compound of Formula (I) would be effective at preventing the development of the neurodegenerative disease and LRRK2 mediated disorder Alzheimer’s disease in a subject in need, nor preventing the development of Parkinson’s disease nor Amyotrophic Lateral Sclerosis in the afflicted patient as recited in the present claims.
PNG
media_image1.png
375
608
media_image1.png
Greyscale
Secondly, Candito (U.S. Patent 11,161,854 published 11/02/2021) represents the state of the prior art regarding LRRK2 inhibitors for treating Alzheimer’s disease and Parkinson’s disease in a subject in need. Candito teaches treating Alzheimer’s disease and Parkinson’s disease in a subject in need comprising administering an indazole compound of Formula (I). Embraced within Formula (I) of Candito is compound 10.4.2 as a potent inhibitor of LRRK2 (col. 152; Table 11). Compound 10.4.2 reads on the present claims of R1 and R3 are independently H, X and Z are each independently CH, Y is N, m is 2 n is 1 and R6 is alkyl. The difference between compound 10.4.2 of Candito and the presently claimed compounds is that R2 on Candito is a polycyclic C6 carbocyclic ring while the presently claimed only embraces a C3-C10 monocyclic carbocyclic ring. Candito teaches the treatment of Parkinson’s disease, Alzheimer’s disease and Amyotrophic Lateral Sclerosis in a subject in need comprising administering a therapeutically effective amount of the LRRK2 inhibitor of Formula (I) (claims 1, 9-10). Nowhere within the boundaries of Candito does it disclose that the administration of said LRRK2 inhibitor would be effective at preventing the development of the neurodegenerative disease and LRRK2 mediated disorder Alzheimer’s disease in a subject in need, nor preventing the development of Parkinson’s disease nor Amyotrophic Lateral Sclerosis in the afflicted patient.
Thirdly, Gray (WO2020/081682 published 04/23/2020 with U.S. Provisional Application 62746283 filed 10/16/2018) represents the state of the prior art of treating LRRK2 mediated disorders with bifunctional degrading compounds that compose a degrader of LRRK2 linked to a linker L and a degron D. Gray teaches treating the LRRK2 mediated disorder Parkinson’s disease in a subject in need comprising administering a bifunctional degrading compounds that compose a degrader of LRRK2 linked to a linker L and a degron D (abstract, [0006], Figure 1, claims 1 and 24-25). Gray teaches that indazole LRRK2 inhibitors of Formula (I-2a) are suitable components for the LRKK2 degrader portion of the bifunctional molecule, linked to a linker L and a degron D, which comprises the structure of Formula (a1) wherein Q1-Q4 are each independently CH, W is C(O), X and Z are each independently O, and Rn, A and G are each independently H (pages 105-106, claims 1, 22) ([0086]-[0088], claims 1, 5-6 and 22). Nowhere within the boundaries of Gray does it disclose that the administration of bifunctional degrading compounds that compose a degrader of LRRK2 linked to a linker L and a degron D would be effective at preventing the development of the neurodegenerative disease and LRRK2 mediated disorder Alzheimer’s disease in a subject in need, nor preventing the development of Parkinson’s disease nor amyotrophic lateral sclerosis in the afflicted patient.
Kuraszkiewicz (Frontiers Neuroscience Vol. 14 published 05/25/2020) represents the state of the prior art of prevention of amyotrophic lateral sclerosis. Kuraszkiewicz teaches that ALS is fatal, progressive neurodegenerative disease characterized by the loss of motoneuron function in the brain, brainstem and spinal cord. While Kuraszkiewicz teaches that risk factors for ALS include advanced age, increased glutamate uptake and stress, Kuraszkiewicz teaches that the pathogenesis of ALS remains to be defined so neither effective therapies nor prophylactic measures have yet been developed (pages 1-4).
Greicius (Journal of Neurol Neurosurg Psychiatry Vol. 72 pages 691-700 Published 2002) also represents the state of the prior art. Greicius teaches diagnosis and taxonomy of Alzheimer’s disease. Greicius teaches that Alzheimer’s disease symptoms include deficits in at least two areas of cognition, progressive worsening of memory and other cognitive functions without any other neurological disorder that could explain the cognitive decline, the development of amyloid plaques, neurofibrillary tangles and neuronal loss, wherein the plaques and tangles lead to neuronal loss (page 692 left-right col.). Post-mortem analysis of brain tissue for the characteristics of amyloid plaques is considered necessary for a definitive diagnosis. This is because the art has yet to recognize its presence in essentially all cases. However, to achieve diagnostic status took years of evaluating procedures, both pre and post-mortem, confirming that every case had a degree of this pathology. Even so, diagnostic application is often problematic given variable peptide expression patterns among clinically similar and dissimilar disease states (page 696-697). Greicius further teaches that while there is promise of many agents to prevent Alzheimer’s disease, none have yet proven to be effective (page 693 left col., page 697 right col.).
Given that there a only a few factors that are recognized to have moderate, if any, predictive value in determining the likelihood that patients develop such a disease or to even determine whether patients actually have such a disease, since many of the early signs of Alzheimer’s disease, Parkinson’s disease or Amyotrophic Lateral Sclerosis are common complaints of aging or result from other neurological conditions, such as depression, where memory impairment is not present, one of ordinary skill in the art would not accept on its face Applicant's statement that the onset of the LRRK2 mediated disorders Alzheimer’s disease, Parkinson’s disease or Amyotrophic Lateral Sclerosis could be effectively prevented using the presently claimed compound of Formula (I).
In fact, such complexity of diagnosis precludes a common, art-accepted protocol for preventing or delaying the onset of Alzheimer’s disease or Amyotrophic Lateral Sclerosis or Parkinson’s disease in any patient, given that the circumstances or risk factors are unique to that individual and must be considered on a case-by-case basis when determining the most effective approach to in delaying or preventing said neurological disorders, let alone the fact that while there is promise of many agents to prevent Alzheimer’s disease, Parkinson’s disease and Amyotrophic Lateral Sclerosis, none have yet proven to be effective.
In other words, not only is the population in need of such treatment not well defined in the art because of the difficulties associated with making an accurate diagnosis, but the disease is also sufficiently complicated and poorly understood such that the idea that any active agent (including the presently claimed compounds of Formula (I) would be capable of preventing the onset of such a condition via its administration would not have been reasonably expected by the skilled artisan. The artisan would have required sufficient direction as to how the administration of the presently claimed active agent(s) could actually determine the population of patients in need of such delay or prevention and how the presently claimed agent(s) could actually delay or prevent Alzheimer's disease, Amyotrophic Lateral Sclerosis or Parkinson’s disease such that the artisan would have been imbued with at least a reasonable expectation of success. Such success would not have been reasonably expected given that the concept of a single agent, or even a combination of agents, that is effective against the development of Alzheimer's disease, Amyotrophic Lateral Sclerosis or Parkinson’s disease would have been unique as cited in Greicius and Kuraszkiewicz above, and, thus, met with a great deal of skepticism.
(4) The level of one of ordinary skill: The level of skill in the art is high and is at least that of a medical doctor with several years of experience in the art of neurodegenerative diseases.
(5) The level of predictability in the art:
The level of predictability in the art is low given that the state of the prior art (Greicius) teaches that while there is promise of many agents to prevent Alzheimer’s disease, Amyotrophic Lateral Sclerosis and Parkinson’s disease, none have yet proven to be effective (Greicius: page 693 left col., page 697 right col.).
(6) The amount of direction provided by the inventor and (7) The existence of working examples:
Applicant provides zero in-vivo working examples with a compound of Formula (I) to treat let alone prevent the LRRK2 mediated disorder Alzheimer’s disease, or Amyotrophic Lateral Sclerosis or Parkinson’s disease. Applicant only demonstrates the capacity of the claimed compounds to inhibit the enzymatic activity of LRRK2 (G2019S) and LRRK2 wild-type protein. Applicant relies on the capacity of the LRRK2 kinase inhibiting compounds of in the State of the Prior art section above to establish that the claimed methodology is enabled in the prior art. In light of the fact that the specification fails to provide the skilled artisan with any direction or guidance as to how the prevention of Alzheimer’s disease, Amyotrophic Lateral Sclerosis or Parkinson’s disease could actually be achieved, since the disclosure is solely directed to the concept of preventing LRRK2 mediated disorders without a working example, the present specification is viewed as lacking an enabling disclosure of the entire scope of the claimed invention and requiring an undue level of experimentation for this aspect of the invention.
(8) The quantity of experimentation needed to make or use the invention based on the content of the disclosure.
The basis for the present rejection is not simply that experimentation would be required, since it is clear from the state of the prior art and Applicant's disclosure that experimentation in this particular art is not at all uncommon, but that the experimentation required in order to practice this aspect of the invention would be undue. Please reference In re Angstadt, 537 F.2d 498, 504, 190 USPQ 214, 219 (CCPA 1976), which states, "The test of enablement is not whether any experimentation is necessary, but whether, if experimentation is necessary, it is undue." (emphasis added) Applicant fails to address the unpredictability in the art by providing adequate direction or guidance as to how to practice this aspect of the invention, in terms of disclosing how to use the presently claimed compounds of Formula (I) such that preventing the onset of Alzheimer’s disease Amyotrophic Lateral Sclerosis or Parkinson’s disease could be reasonably achieved, or even any basis for extrapolating the results shown in the working embodiments. As a result, the specification is viewed as lacking an enabling disclosure of the same.
Conclusion
Claims 26-30 are rejected. Claims 1-25 are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to GEORGE W KOSTURKO whose telephone number is (571)270-5903. The examiner can normally be reached M-F 9:00-5:30.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, CLINTON A BROOKS can be reached at 571-270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/GEORGE W KOSTURKO/Primary Examiner, Art Unit 1621